Deficits in a Simple Visual Go/No-go Discrimination Task in Two Mouse Models of Huntington's Disease

PLoS Currents

Volumn , Issue NOV, 2013, Pages

  Oakeshott, Stephen ^a   Farrar, Andrew ^a   Port, Russell ^a   Cummins Sutphen, Jane ^a   Berger, Jason ^a   Watson Johnson, Judy ^a   Ramboz, Sylvie ^a   Howland, David ^b   Brunner, Dani ^a,c  

^a PSYCHOGENICS INC   (United States)

^b CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL BEHAVIOR; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOLLOW UP; GENOTYPE; HUNTINGTON CHOREA; LIPID STORAGE; MALE; MOUSE; NONHUMAN; TASK PERFORMANCE; VELOCITY; VISUAL DISCRIMINATION; WEIGHT REDUCTION;

EID: 84898639723     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.hd.fe74c94bdd446a0470f6f905a30b5dd1     Document Type: Article

References (35)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington9s disease chromosomes. The Huntington9s Disease Collaborative Research Group. Cell. 1993 Mar 26;72(6):971-83. PubMed PMID:8458085. 8458085.
2. Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008 Jun 11;28(24):6182-95. PubMed PMID:18550760. 18550760.
3. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR. A YAC mouse model for Huntington9s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999 May;23(1):181-92. PubMed PMID:10402204. 10402204.
4. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996 Nov 1;87(3):493-506. PubMed PMID:8898202. 8898202.
5. Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC, Ramboz S, Howland D. Comprehensive Behavioral and Molecular Characterization of a New Knock-In Mouse Model of Huntington9s Disease: zQ175. PLoS One. 2012;7(12):e49838. PubMed PMID:23284626. 23284626.
6. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington9s disease with 140 CAG repeats. J Comp Neurol. 2003 Oct 6;465(1):11-26. PubMed PMID:12926013. 12926013.
7. Roos RA, Hermans J, Vegter-van der Vlis M, van Ommen GJ, Bruyn GW. Duration of illness in Huntington9s disease is not related to age at onset. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):98-100. PubMed PMID:8429330. 8429330.
8. Craufurd D, Snowden J. Neuropsychological and neuropsychiatric aspects of Huntington's Disease In Bates, G., Harper, P.S. & Jones, L. (eds), Huntington9s Disease. 2002 Oxford University Press, Oxford, pp. 62-94.
9. Aron AR, Watkins L, Sahakian BJ, Monsell S, Barker RA, Robbins TW. Task-set switching deficits in early-stage Huntington9s disease: implications for basal ganglia function. J Cogn Neurosci. 2003 Jul 1;15(5):629-42. PubMed PMID:12965037. 12965037.
10. Rodrigues GR, Souza CP, Cetlin RS, de Oliveira DS, Pena-Pereira M, Ujikawa LT, Marques W Jr, Tumas V. Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington9s disease. J Neurol. 2009 Nov;256(11):1809-15. PubMed PMID:19536583. 19536583.
11. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW. Executive and mnemonic functions in early Huntington9s disease. Brain. 1996 Oct;119 (Pt 5):1633-45. PubMed PMID:8931586. 8931586.
12. Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D. Longitudinal evaluation of cognitive disorder in Huntington9s disease. J Int Neuropsychol Soc. 2001 Jan;7(1):33-44. PubMed PMID:11253840. 11253840.
13. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington9s disease mutation. J Neurosci. 1999 Dec 1;19(23):10428-37. PubMed PMID:10575040. 10575040.
14. Brooks SP, Betteridge H, Trueman RC, Jones L, Dunnett SB. Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington9s disease. Brain Res Bull. 2006 Apr 28;69(4):452-7. PubMed PMID:16624677. 16624677.
15. Brooks SP, Janghra N, Higgs GV, Bayram-Weston Z, Heuer A, Jones L, Dunnett SB. Selective cognitive impairment in the YAC128 Huntington9s disease mouse. Brain Res Bull. 2012 Jun 1;88(2-3):121-129. PubMed PMID:21624441. 21624441.
16. Balci F, Day M, Rooney A, Brunner D. Disrupted temporal control in the R6/2 mouse model of Huntington9s disease. Behav Neurosci. 2009 Dec;123(6):1353-1358. PubMed PMID:20001119. 20001119.
17. Oakeshott S, Port RG, Cummins-Sutphen J, Watson-Johnson J, Ramboz S, Park L, Howland D, Brunner D. HD mouse models reveal clear deficits in learning to perform a simple instrumental response. PLoS Curr. 2011 Nov 30;3:RRN1282. PubMed PMID:22512000. 22512000.
18. Trueman RC, Dunnett SB, Brooks SP. Operant-based instrumental learning for analysis of genetically modified models of Huntington9s disease. Brain Res Bull. 2012 Jun 1;88(2-3):261-275. PubMed PMID:21440048. 21440048.
19. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. Characterization of progressive motor deficits in mice transgenic for the human Huntington9s disease mutation. J Neurosci. 1999 Apr 15;19(8):3248-3257. PubMed PMID:10191337. 10191337.
20. Menalled L, El-Khodor BF, Patry M, Suárez-Fariñas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D. Systematic behavioral evaluation of Huntington9s disease transgenic and knock-in mouse models. Neurobiol Dis. 2009 Sep;35(3):319-36. PubMed PMID:19464370. 19464370.
21. Murphy CA, Paterson NE, Oakeshott S, He D, Alosio W, McConnell K, Menalled LB, Farrar AM, Ramboz S, Park L, Howland D, Brunner D. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease. Submitted to Journal of Huntington9s Disease. In review.
22. Singer J. Using SAS PROC MIXED to Fit Multilevel Models, Hierarchical Models, and Individual Growth Models. Journal of Educational and Behavioral Statistics. 1998 23 323.
23. Trueman RC, Brooks SP, Jones L, Dunnett SB. The operant serial implicit learning task reveals early onset motor learning deficits in the Hdh knock-in mouse model of Huntington9s disease. Eur J Neurosci. 2007 Jan;25(2):551-8. PubMed PMID:17284197. 17284197.
24. Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington9s disease. J Neurosci. 2005 Apr 20;25(16):4169-4180. PubMed PMID:15843620. 15843620.
25. Morton AJ, Skillings E, Bussey TJ, Saksida LM. Measuring cognitive deficits in disabled mice using an automated interactive touchscreen system. Nat Methods. 2006 Oct;3(10):767. PubMed PMID:16990806. 16990806.
26. Hellemans KG, Nobrega JN, Olmstead MC. Early environmental experience alters baseline and ethanol-induced cognitive impulsivity: relationship to forebrain 5-HT1A receptor binding. Behav Brain Res. 2005 Apr 30;159(2):207-20. PubMed PMID:15817184. 15817184.
27. Anker JJ, Zlebnik NE, Gliddon LA, Carroll ME. Performance under a Go/No-go task in rats selected for high and low impulsivity with a delay-discounting procedure. Behav Pharmacol. 2009 Sep;20(5-6):406-14. PubMed PMID:19696658. 19696658.
28. Marusich JA, Darna M, Charnigo RJ, Dwoskin LP, Bardo MT. A multivariate assessment of individual differences in sensation seeking and impulsivity as predictors of amphetamine self-administration and prefrontal dopamine function in rats. Exp Clin Psychopharmacol. 2011 Aug;19(4):275-84. PubMed PMID:21574722. 21574722.
29. Schachar R, Logan GD, Robaey P, Chen S, Ickowicz A, Barr C. Restraint and cancellation: multiple inhibition deficits in attention deficit hyperactivity disorder. J Abnorm Child Psychol. 2007 Apr;35(2):229-38. PubMed PMID:17351752. 17351752.
30. Logan GD, Cowan WB. On the ability to inhibit thought and action-a theory of an act of control. Psychol Rev 1984 91:295-327.
31. Eagle DM, Bari A, Robbins TW. The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl). 2008 Aug;199(3):439-456. PubMed PMID:18542931. 18542931.
32. Gilmour G, Arguello A, Bari A, Brown VJ, Carter C, Floresco SB, Jentsch DJ, Tait DS, Young JW, Robbins TW. Measuring the construct of executive control in schizophrenia: Defining and validating translational animal paradigms for discovery research. Neurosci Biobehav Rev. 2012 Apr 23. PubMed PMID:22548905. 22548905.
33. Lawrence AD, Sahakian BJ, Rogers RD, Hodge JR, Robbins TW. Discrimination, reversal, and shift learning in Huntington9s disease: mechanisms of impaired response selection. Neuropsychologia. 1999 Nov;37(12):1359-74. PubMed PMID:10606011. 10606011.
34. Starkstein SE, Brandt J, Bylsma F, Peyser C, Folstein M, Folstein SE. Neuropsychological correlates of brain atrophy in Huntington9s disease: a magnetic resonance imaging study. Neuroradiology. 1992;34(6):487-9. PubMed PMID:1436456. 1436456.
35. Sprengelmeyer R, Lange H, Hömberg V. The pattern of attentional deficits in Huntington9s disease. Brain. 1995 Feb;118 (Pt 1):145-52. PubMed PMID:7895000. 7895000.